Information on the EAMS scientific opinion given to nivolumab for lung cancer, including the public assessment report.

Nivolumab for lung cancer EAMS public assessment report

This file may not be suitable for users of assistive technology.Request a different format.

 

 

 
 

 

Nivolumab for lung cancer treatment protocol for patients

This file may not be suitable for users of assistive technology.Request a different format.

Nivolumab for lung cancer treatment protocol for healthcare professionals

This file may not be suitable for users of assistive technology.Request a different format.

Nivolumab for lung cancer treatment protocol on the pharmacovigilance system

This file may not be suitable for users of assistive technology.Request a different format.

This positive scientific opinion was issued to Bristol-Myers Squibb Pharmaceutical Limited on 19 June 2015 for nivolumab, in treatment of advanced lung cancer (characterised by squamous non-small cells), which has spread or cannot be removed by surgery following other cancer chemotherapies.

The scientific opinion includes:

  • a public assessment report
  • a treatment protocol:
  • for healthcare professionals
  • for patients
  • on the pharmacovigilance system

 

 

Posted on the UK MHRA website on 29 June 2015